
Tyra Biosciences (TYRA) Stock Forecast & Price Target
Tyra Biosciences (TYRA) Analyst Ratings
Bulls say
Tyra Biosciences is a promising biotechnology company with a focused pipeline of precision medicines for targeted oncology and genetically defined conditions. Powered by their in-house precision medicine platform, SNAP, the company is able to rapidly and accurately design and predict the efficacy, selectivity, and tolerability of their drug candidates. With promising clinical data for their FGFR3, FGFR4/3, and FGFR1/2/3 drug candidates, as well as a strong safety profile, Tyra has potential for success in the competitive biotechnology market.
Bears say
Tyra Biosciences is facing several fundamental challenges, with its most recent clinical data falling well below expectations and a narrower outlook for dabogratinib after a second oncology dataset failed to demonstrate the expected efficacy. Its current pipeline is heavily reliant on the success of dabogratinib and TYRA-200, which carry significant risks and uncertainties. The company's limited market niche and potential for dilution also present concerns, further contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Tyra Biosciences (TYRA) Analyst Forecast & Price Prediction
Start investing in Tyra Biosciences (TYRA)
Order type
Buy in
Order amount
Est. shares
0 shares